Immune Tolerance After
Living Donor Kidney Transplant


NOW ENROLLING

If you plan to receive a kidney transplant from a living donor, you and your living donor may be eligible to participate in a research study called the FREEDOM-1 Study. The FREEDOM-1 Study is evaluating a treatment that could eliminate the need for anti-rejection drugs among living donor kidney transplant recipients.

This website provides you with an overview of the study and important information for donors and recipients. Talk with your doctor to learn more details.

To request additional information, please fill out our contact form here

 

The FREEDOM-1 Study

A randomized, controlled, multi-center, safety and efficacy study of FCR001 cell-based therapy relative to a tacrolimus and mycophenolate-based regimen in de novo living donor renal transplant recipients, and safety in FCR001 donors (the FREEDOM-1 study)

Complete study information

Talaris This site is sponsored by Talaris Therapeutics